Articles with public access mandates - Jeremy RossLearn more
Not available anywhere: 3
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind …
SK Kumar, SJ Harrison, M Cavo, J de la Rubia, R Popat, C Gasparetto, ...
The Lancet Oncology 21 (12), 1630-1642, 2020
Mandates: US National Institutes of Health, National Institute for Health Research, UK
STAT3: an important regulator of multiple cytokine functions
SM Stepkowski, W Chen, JA Ross, ZS Nagy, RA Kirken
Transplantation 85 (10), 1372-1377, 2008
Mandates: US National Institutes of Health
Analysis of Janus tyrosine kinase phosphorylation and activation
JA Ross, G Rodriguez, RA Kirken
JAK-STAT Signalling: Methods and Protocols, 3-20, 2013
Mandates: US National Institutes of Health
Available somewhere: 27
Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma
MS Davids, AW Roberts, JF Seymour, JM Pagel, BS Kahl, WG Wierda, ...
Journal of Clinical Oncology 35 (8), 826-833, 2017
Mandates: US National Institutes of Health
Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma
VA Pullarkat, NJ Lacayo, E Jabbour, JE Rubnitz, A Bajel, TW Laetsch, ...
Cancer discovery 11 (6), 1440-1453, 2021
Mandates: US National Institutes of Health
Searching in mother nature for anti-cancer activity: anti-proliferative and pro-apoptotic effect elicited by green barley on leukemia/lymphoma cells
E Robles-Escajeda, D Lerma, AM Nyakeriga, JA Ross, RA Kirken, ...
PloS one 8 (9), e73508, 2013
Mandates: US National Institutes of Health
Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t (11; 14) multiple myeloma
JL Kaufman, C Gasparetto, FH Schjesvold, P Moreau, C Touzeau, ...
American journal of hematology 96 (4), 418-427, 2021
Mandates: US National Institutes of Health
A phase I first-in-human study of ABBV-383, a B-cell maturation antigen× CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma
A D'souza, N Shah, C Rodriguez, PM Voorhees, K Weisel, OF Bueno, ...
Journal of Clinical Oncology 40 (31), 3576-3586, 2022
Mandates: US National Institutes of Health
Forskolin inducible cAMP pathway
ZS Nagy, RA Kirken, G Rodriguez, JA Ross
Mandates: US National Institutes of Health
Phosphoproteomic analysis of the human pathogen Trypanosoma cruzi at the epimastigote stage
ES Nakayasu, MR Gaynor, TJP Sobreira, JA Ross, IC Almeida
Proteomics 9 (13), 3489-3506, 2009
Mandates: US National Institutes of Health
Signal transducer and activator of transcription 5b (Stat5b) serine 193 is a novel cytokine-induced phospho-regulatory site that is constitutively activated in primary …
A Mitra, JA Ross, G Rodriguez, ZS Nagy, HL Wilson, RA Kirken
Journal of Biological Chemistry 287 (20), 16596-16608, 2012
Mandates: US National Institutes of Health
Protein phosphatase 2A regulates interleukin-2 receptor complex formation and JAK3/STAT5 activation
JA Ross, H Cheng, ZS Nagy, JA Frost, RA Kirken
Journal of Biological Chemistry 285 (6), 3582-3591, 2010
Mandates: US National Institutes of Health
Minimal residual disease in myeloma: application for clinical care and new drug registration
KC Anderson, D Auclair, SJ Adam, A Agarwal, M Anderson, ...
Clinical Cancer Research 27 (19), 5195-5212, 2021
Mandates: US National Institutes of Health
STAT5 regulation of BCL10 parallels constitutive NFkappaB activation in lymphoid tumor cells
ZS Nagy, MJ LeBaron, JA Ross, A Mitra, H Rui, RA Kirken
Mol Cancer 8, 67, 2009
Mandates: US National Institutes of Health
The prohibitin protein complex promotes mitochondrial stabilization and cell survival in hematologic malignancies
JA Ross, E Robles-Escajeda, DM Oaxaca, DL Padilla, RA Kirken
Oncotarget 8 (39), 65445, 2017
Mandates: US National Institutes of Health
Green barley mitigates cytotoxicity in human lymphocytes undergoing aggressive oxidative stress, via activation of both the Lyn/PI3K/Akt and MAPK/ERK pathways
BE Ruiz-Medina, D Lerma, M Hwang, JA Ross, R Skouta, RJ Aguilera, ...
Scientific reports 9 (1), 6005, 2019
Mandates: US National Science Foundation, US National Institutes of Health, Lung …
Phosphorylation of human Jak3 at tyrosines 904 and 939 positively regulates its activity
H Cheng, JA Ross, JA Frost, RA Kirken
Molecular and cellular biology 28 (7), 2271-2282, 2008
Mandates: US National Institutes of Health
Lenvatinib with or without everolimus in patients with metastatic renal cell carcinoma after immune checkpoint inhibitors and vascular endothelial growth factor receptor …
AJ Wiele, TK Bathala, AW Hahn, L Xiao, M Duran, JA Ross, E Jonasch, ...
The oncologist 26 (6), 476-482, 2021
Mandates: US Department of Defense, US National Institutes of Health
MUC1 glycopeptide epitopes predicted by computational glycomics
W Song, ES Delyria, J Chen, W Huang, JS Lee, EA Mittendorf, N Ibrahim, ...
International journal of oncology 41 (6), 1977-1984, 2012
Mandates: US National Institutes of Health
Interleukin-2 receptor β Thr-450 phosphorylation is a positive regulator for receptor complex stability and activation of signaling molecules
BE Ruiz-Medina, JA Ross, RA Kirken
Journal of Biological Chemistry 290 (34), 20972-20983, 2015
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program